Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.
Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.
Erasca, Inc. reported positive preliminary Phase 1 dose escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. Early results come from the AURORAS-1 trial in the United States and the JYP0015M101 trial in China.
The studies enroll patients with colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma, tumor types where KRAS mutations affect an estimated 74,000, 55,000 and 50,000 patients per year in the United States. Erasca has already started ERAS-0015 monotherapy expansion and combination dose escalation cohorts in the United States earlier than its prior guidance.
The company emphasizes that the data are preliminary, include information from a third-party licensor and involve cross-study comparisons that are inherently limited. It highlights multiple development and regulatory risks, including the possibility that future, more complete trial results may differ from current observations.
Erasca, Inc. reported positive preliminary Phase 1 dose escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. Early results come from the AURORAS-1 trial in the United States and the JYP0015M101 trial in China.
The studies enroll patients with colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma, tumor types where KRAS mutations affect an estimated 74,000, 55,000 and 50,000 patients per year in the United States. Erasca has already started ERAS-0015 monotherapy expansion and combination dose escalation cohorts in the United States earlier than its prior guidance.
The company emphasizes that the data are preliminary, include information from a third-party licensor and involve cross-study comparisons that are inherently limited. It highlights multiple development and regulatory risks, including the possibility that future, more complete trial results may differ from current observations.
Erasca, Inc. updated the expected timing for initial Phase 1 monotherapy data from its pan-RAS molecular glue ERAS-0015, now guiding that data from the AURORAS-1 and JYP0015M101 trials will be available no later than mid-May 2026, compared with its prior expectation of the first half of 2026.
AURORAS-1 is evaluating ERAS-0015 in patients with RAS-mutant solid tumors, while licensor Guangzhou Joyo Pharmatech Co., Ltd. is running JYP0015M101 in China in patients with advanced solid tumors harboring specific RAS mutations. The company also highlights typical forward-looking statement risks and directs readers to its risk factor disclosures.
Erasca Foundation reported proposed sales of Common stock in Form 144/A. The filing lists sales dated 01/15/2026, 02/17/2026, and 03/16/2026 with amounts $68,573.87, $99,245.03, and $116,855.46 respectively. The entries are recorded under Erasca Foundation's address in San Diego and identify the securities as Common stock.
Erasca Foundation reported sale transactions of Common stock via Form 144 and lists multiple recent dispositions by the foundation. The filing itemizes dated transfers on 01/15/2026, 02/17/2026, and 03/16/2026 with corresponding amounts shown in the excerpt.
Erasca, Inc. Chief Legal Officer Ebun Garner exercised stock options and sold shares in a planned transaction. On April 1, 2026, Garner exercised options to acquire 80,000 shares of common stock at $1.70 per share, converting a derivative position into common stock.
That same day, Garner sold 80,000 shares of common stock at a weighted-average price of $16.40 per share in open-market transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 30, 2024. Following these transactions, Garner directly held 25,076 shares of Erasca common stock.
Erasca, Inc. filed a Form 144 reporting a proposed sale of 80,000 shares of Common Stock associated with a stock option, planned for 04/01/2026 and to be settled for cash. The filing shows an aggregate value of $1,312,354.68 and lists 310,799,547 shares outstanding as of 04/01/2026 as a context figure. The filer also reported a prior sale of 120,000 shares on 01/07/2026 for $670,809.15.
Erasca, Inc. Form 144 filing notifies proposed sales of Common stock by the Erasca Foundation as reported on the form. The filing lists multiple entries with a recurring figure 8333 associated with each sale line and transaction dates such as 02/17/2026, 01/15/2026, and 12/15/2025.
Examples shown include Erasca Foundation entries dated 02/17/2026 (8333) and 01/15/2026 (8333). The filing identifies Nasdaq as the market and includes an apparent reporting date of 03/16/2026.
Erasca, Inc. files its annual report describing a focused strategy to develop precision oncology drugs that shut down the RAS/MAPK pathway in cancer. The company highlights two clinical-stage programs, ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor), plus discovery-stage EGFR antibody ERAS-12.
Early Phase 1 data for ERAS-0015 show partial responses at low doses with favorable safety and linear pharmacokinetics. Erasca exercised its option to expand territorial rights for ERAS-0015 globally (including mainland China) under its Joyo license and is preparing multiple monotherapy and combination readouts in 2026–2027.
The company streamlined its portfolio by terminating several legacy programs and license agreements to concentrate resources on its RAS franchise and EGFR antibody platform. As of June 30, 2025, non-affiliate common stock held an aggregate market value of $316.4 million, and common shares outstanding totaled 310,799,547 as of March 5, 2026.
Erasca, Inc. reported fourth quarter and full year 2025 results alongside business and pipeline updates. For 2025, net loss narrowed to $124.5 million, or $(0.44) per share, from $161.7 million, or $(0.69) per share, in 2024 as operating expenses declined.
Research and development expenses fell to $92.9 million from $115.4 million, while general and administrative expenses decreased to $38.6 million from $41.7 million. Cash, cash equivalents, and marketable securities were $341.8 million as of December 31, 2025, down from $440.5 million a year earlier.
The company completed an upsized public offering in January 2026, raising approximately $258.8 million in gross proceeds and expects pro forma cash of $434 million to fund operations into the second half of 2028. Erasca highlighted encouraging early clinical activity for ERAS-0015, continued advancement of ERAS-4001, and new U.S. composition-of-matter patents supporting its RAS-targeting franchise, with multiple Phase 1 data readouts and trial expansions planned in 2026 and 2027.